Zombie portfolio companies is the phrase private equity has settled on for its $860 billion problem. The roughly 4,500 U.S. businesses now classified as zombie portfolio companies are sitting in sponsor portfolios well past the exit dates their investment theses assumed. The industry is describing this as a liquidity problem, a timing problem, a market problem, essentially a backlog that a friendlier exit window will eventually clear.
Read the underlying data like we do, and something else comes into focus. Private equity does not primarily have a zombie problem, it has a value-creation accountability problem. Age is the symptom the market can see, but it is not the disease. If PE wants to get out of this problem, they are going to need to take a more proactive approach and start treating the disease.
The numbers behind zombie portfolio companies
PitchBook’s new research on aging assets puts the scale in plain terms. Of the 13,509 companies backed by U.S. private equity firms, roughly 33.8% have been held for five years or longer. More than $860 billion in net asset value now sits inside funds older than seven years, the third consecutive annual increase and the highest concentration since 2016.
Bain’s Global Private Equity Report 2026 frames the same logjam globally: around 32,000 unsold companies carrying roughly $3.8 trillion in value, with holding periods at exit stretched to about seven years against five to six across most of the prior decade. Distributions to limited partners have stayed below 15% of net asset value for four straight years, an industry record.
But the figures worth diving into when analyzing the core problem are:
- 13,509 U.S. companies currently sit in private equity sponsor portfolios
- Roughly 33.8% — north of 4,500 businesses — have been held five years or longer
- More than $860 billion in net asset value is parked in funds older than seven years
- 3,332 of those companies have completed no transaction of any kind since the end of 2021 — no add-on, no recapitalization, no refinancing
- Distributions have run below 15% of net asset value for four consecutive years
That fourth line tells the real story that matters. Those are not businesses waiting out an unfriendly exit window, they are businesses where nothing has happened for four years. The exit market did not close on them, the value creation work did.
Time is a symptom, not a diagnosis
Age alone does not make a zombie portfolio company. A healthy business held for eight years may still be compounding enterprise value on a perfectly defensible schedule. That’s reasonable. A company held for three years may be economically undead and throwing off enough cash to avoid collapse, but not enough growth, differentiation, or buyer relevance to justify what it is carried at. Not acceptable.
The distinction that matters is not vintage year, it is the difference between two things that the last decade allowed us to confuse. Investment return can be manufactured through leverage, timing, financial structuring, and multiple expansion. Enterprise value creation comes from making the underlying business more capable, more durable, more scalable, and more transferable than it was on the day it was bought. Cheap debt let both look identical on a return chart, but recent rate normalization pulled them apart.
Take a company acquired at 12× and marked today at 10×. If EBITDA has grown from $10 million to $18 million, real value was built and the multiple compression is an inconvenience. If EBITDA is still $10 million, or has been held at $10 million through cost discipline, then the investment thesis was leaning on market conditions rather than on enterprise development. Same headline multiple, entirely different company valuation.
Bain’s own numbers make the point logically. Across fifteen years of buyout vintages, internal rate of return stagnates around year seven and declines from there. Holding longer is not neutral. It is a decision with a cost, and the cost compounds. Bain’s conclusion is a systems argument, not a market-timing one: “the winning firms will build systems, not slogans.”
That is the correct frame, and it is precisely the frame the zombie portfolio companies label obscures.
Not all zombie portfolio companies are the same
Counting years in a portfolio is a sorting method, not a diagnosis. Seven distinct conditions get flattened into the same word, and each one calls for a different response.
- Aging but compounding. Value is still building; the exit window is genuinely unfavorable. Hold selectively and maintain exit readiness.
- Operationally stalled. Revenue or EBITDA has plateaued and the original plan has stopped working. Rebuild the value-creation roadmap from current conditions.
- Financially trapped. Debt service, covenants, or refinancing risk prevent the investment growth would require. Recapitalize or restructure.
- Strategically irrelevant. The business is viable but has lost differentiation and buyer relevance. Reposition, acquire capability, or combine.
- Optically healthy. EBITDA has been protected through cuts while underlying capability erodes. Restore investment in growth and organizational capacity.
- Structurally impaired. The business cannot reasonably reach an acceptable exit value. Sell, wind down, or separate what is recoverable.
- Exit-ready but mismatched. The business is sound; the buyer set, timing, or transaction structure was misidentified. Redesign the pathway.
“Wait for the market to improve” is a reasonable answer for the first condition, but it is actively destructive for the other six. A vintage-year report cannot tell an owner which one they hold.
The most dangerous zombie portfolio company looks healthy
Here is a scary fact that does not show up in a NAV schedule. Zombie portfolio companies frequently look better on paper the longer the underlying business deteriorates.
A sponsor can extend a company’s apparent life by cutting headcount, deferring R&D, postponing technology investment, throttling customer acquisition, delaying maintenance, replacing experienced executives with less expensive ones, bolting on acquisitions without integrating them, or refinancing the asset into a continuation vehicle. Every one of those moves protects near-term EBITDA and reported value, yet several of them slowly destroy the exact capabilities a future buyer will underwrite.
The company looks alive financially while decaying operationally. This gives us a working definition worth adopting: a zombie portfolio company is not simply one that cannot be sold, it is one whose reported value has drifted away from its capacity to create future value.
Continuation vehicles deserve a specific mention here. Bain notes they account for less than 10% of exit value and function as a partial fix rather than a structural one. The honest question in any continuation decision is whether the vehicle is solving a timing problem or concealing a value problem. Those are not the same transaction, even when the paperwork looks identical.
Three questions that separate value from vintage
Sorting zombie portfolio companies by holding period produces a list. Sorting them by these three questions produces an agenda.
One: is the business creating value? This examines operating performance rather than fund age: organic revenue growth, margin quality, recurring versus transactional revenue mix, customer retention and concentration, pricing power, innovation pipeline, management depth, process scalability, data and technology maturity, cash conversion, and capital efficiency.
Two: is that value transferable? A company can be profitable and still be difficult to acquire. Transferability turns on founder or single-executive dependence, undocumented processes, customer and supplier concentration, weak financial controls, unresolved legal or regulatory exposure, unintegrated acquisitions, fragile technology, and heavy working-capital requirements. This is the largest blind spot in conventional value-creation planning. Producing earnings is not enough. A buyer has to believe those earnings survive a change in ownership.
Three: is there a credible realization pathway? Who are the logical strategic buyers, and what capability, market position, customer base, or cash flow are they actually acquiring? What objection blocks the transaction, and can it be removed? Does the business work better as an add-on than as a platform? Are the parts worth more than the whole? And what has to be true twelve to twenty-four months from now to support the exit?
Those three questions convert “exit someday” into an operating plan with owners and dates attached.
What the backlog of zombie portfolio companies is actually telling us
The backlog of zombie portfolio companies is not evidence that private equity got unlucky on timing, it is evidence that value creation cannot begin two years before an expected sale. It has to be designed at acquisition, translated into measurable operating priorities, monitored across the full holding period, and connected continuously to buyer relevance. Bain’s “12 is the new 5” framing, the argument that today’s entry multiples demand materially faster EBITDA growth, is a demand for exactly that kind of system.
A business does not suddenly become unmarketable in year seven. The conditions that made it unmarketable accumulated, unnoticed or unaddressed, across years one through six.
This is Redtail’s case for treating a portfolio company as a business system rather than a set of silos, and for diagnosing structural conditions before the financial lag makes them visible. It is the same reason deal price is not the same as value created. The Enterprise Value Creation Roadmap was built for that examination. It surfaces where enterprise value is being created or eroded across the business system, and it models the gap between what a company is marked at and what a buyer would actually underwrite.
Kyle Walters, PitchBook’s private equity analyst, told Fortune that “these companies can’t sit in the portfolio forever.” He is right. Zombie portfolio companies do not sit in portfolios forever; something resolves them, a strategic buyer, a wind-down, or a write-off. Decay is a mechanism, not a strategy, and patience is not a substitute for a plan.
Time does not create enterprise value. It only reveals whether value was being created all along.
Shout out to Allie Garfinkle with Fortune’s Term Sheet, for outlining the PE Zombie problem in the August 25th edition.
